RADI-15. Radiotheranostic Approach in Brain Tumor. (9th August 2021)

• Record Type: Journal Article
• Authors: Nemati, Reza; Rekabpour, Seyed Javad; Jokar, Narges; Ahmadzadehfar, Hojjat; Shooli, Hossein; Jafari, Esmail; Assadi, Majid
• Is Part Of: Neuro-oncology advances. Volume 3(2021)Supplement 3
• Page Start: iii21
• Page End: iii21
• Publication Date: 2021-08-09
• Subjects: 616.99481
• DOI: 10.1093/noajnl/vdab071.085
• Languages: English
• ISSNs: 2632-2498

Abstract

Abstract: Purpose: The aim of this study is feasibility and potential treatment of targeted radionuclide theranostic approach for patients with brain tumors. Methods: For the period 2020–2021, 6 child and adult patients who had been diagnosed with brain tumors were treated using theranostic approach followed by refractory to conventional therapy. Two patients that were presented with HER-2 positive, ER and PR negative breast cancer and brain metastases as well as a history of several cycles of chemotherapy sessions and radiotherapy using gamma knife were treated with 177Lu-Trastuzumab (Herceptin). Three other patients with primary brain tumor underwent peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE. The last case was a patient with refractory primary cerebral lymphoma to standard therapy with confirmed CD20-positive B-cell lymphoma who underwent 177Lu-Rituximab. Results: A two women with HER-2 positive breast cancer and brain metastasis underwent two cycles of 177Lu-trastuzumab. Post-therapy assessment showed some improvement. Next, a man with a high-grade glioma tumor in the left frontal lobe with history of debunking surgery in combination with chemoradiation received 177Lu-DOTATATE that resulted in a short-term stable situation. Another patient presented with a right cerebellopontine angle meningioma underwent PRRT with 177Lu-DOTATATE. She had a stable disease with some improvement in the clinical status. Also, a girl with an astrocytoma in suprasellar cistern underwent 2 cycles of 177Lu-DOTATATE. The complete response was designed. Finally, a patient with refractory primary cerebral lymphoma received 177Lu-Rituximab. Conclusion: Nuclear oncology in the field of neuro-oncology (neuroradiotheranostics) has been toward a personalized approach, effective and safe therapy. These preliminary studies might demonstrate feasibility and therapeutic potential of theranostics in patients with primary, relapsed or metastasis brain tumors. Further studies preferentially well-designed multicenter international clinical trial is warranted.